Otsuka Pharmaceutical Deal History & Licensing Activity
Otsuka Pharmaceutical is a large pharma headquartered in Japan. Over the past three years, Otsuka Pharmaceutical has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (1 deal).
Deals (12mo)
1
Active Trials
20
Top Modality
Small Molecules
Focus Area
Rare Disease
Otsuka Pharmaceutical Pipeline Focus
Therapeutic areas and modalities where Otsuka Pharmaceutical is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Otsuka Pharmaceutical Strategic Signals
Key indicators of Otsuka Pharmaceutical's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Otsuka Pharmaceutical's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Otsuka Pharmaceutical Licensing & Deal Activity
Otsuka Pharmaceutical is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Otsuka Pharmaceutical ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Otsuka Pharmaceutical include Rare Disease (1 deal and trial), and Immunology (1 deal and trial). In terms of modality, Otsuka Pharmaceutical has shown particular interest in small molecules, bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Otsuka Pharmaceutical and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Otsuka Pharmaceutical's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.